Zobrazeno 1 - 8
of 8
pro vyhledávání: '"35"'
Autor:
Masakazu Toi, Zhipeng Wang, Kazuharu Shimizu, Norikazu Masuda, Takayuki Ueno, Yoshiki Mikami, Fumiaki Sato, Akira Myomoto, Satoko Takizawa, Gozoh Tsujimoto
Publikováno v:
Cancer Research. 72:P5-10
[Background and Aim] Although Trastuzumab has been used for HER2(+) breast cancer, the treatment response of Trastuzumab therapy depends on unknown mechanisms among individual cases. In order to avoid unnecessary adverse events and to lighten financi
Publikováno v:
Cancer Research. 81:PS2-12
Background Oncotype Dx Recurrence Score (ODX-RS) is a 21-gene assay used to predict recurrence in early stage breast cancer and guide chemotherapy decisions. Invasive lobular carcinomas (ILC) represent approximately 10-15% of all breast cancers. Many
Publikováno v:
Cancer Research. 80:P6-10
Background: Ductal carcinoma in situ (DCIS) is considered a non-obligate precursor of invasive breast cancer (IBC). It is estimated that 5-14% of women diagnosed with DCIS experience an ipsilateral IBC. Current clinical criteria do not discriminate w
Autor:
Fumiaki Sato, Zhipeng Wang, Takayuki Ueno, Akira Myomoto, Satoko Takizawa, Feng Ling Pu, Norikazu Masuda, Yoshiki Mikami, Kazuharu Shimizu, Shigehira Saji, Masakazu Toi
Publikováno v:
Cancer Research. 73:1937-1937
[Background and Aim] Although Trastuzumab has been used for HER2(+) breast cancer, the treatment response of Trastuzumab therapy depends on unknown mechanisms among individual cases. In order to avoid unnecessary adverse events and to lighten financi
Autor:
Tapashi Dalvi, Susan McCutcheon, Kimmie K. McLaurin, Jenna Collins, James Bennett, Beth L. Nordstrom, Brian R. Murphy, Josefa Maria Briceno, Robert Hettle
Publikováno v:
Cancer Research. 79:P1-09
Background: Limited data exist on the natural history (treated with standard of care) of metastatic breast cancer (mBC) characterized by germline breast cancer susceptibility gene mutations (gBRCAm). Real-world data examining survival for patients wi
Publikováno v:
Cancer Research. 75:P5-10
Background: Loss of progesterone receptor expression is known to be a predictor of Luminal-B subtype, and is of independent prognostic significance in luminal type breast cancer. However, the threshold of PgR status in IHC has been subject to debate,
Publikováno v:
Cancer Research. 70:P6-01
Background: Benign papillary lesions of the breast including papilloma and papillomatosis are believed to be associated with a low risk of developing breast cancer. The risk of breast cancer development in patients who have an atypical papilloma or w
Autor:
O.C. Freedman, M. Lax, William R. Geddie, Mark Clemons, C E Simmons, Naomi Miller, J. Napolskikh, Eitan Amir, George Dranitsaris, H. Maung
Publikováno v:
Cancer Research. 69:2023-2023
Purpose: Decisions about systemic treatment of women with metastatic breast cancer are often based on estrogen receptor (ER), progesterone receptor (PgR), and HER2/neu status of the primary tumour. This study prospectively investigated concordance in